Both companies held general meetings on May 27 to vote on the proposed merger that will see Baxalta stockholders, who were initially reticent of a merger arrangement, receive $18.00 in cash and 0.1482 Shire ADS per Baxalta share – the deal agreed back in January 2016.
Shire & Baxalta Seal The Deal
Shire PLC and Baxalta Inc. shareholders have both voted in favor of the latter's sale to rare disease focused Shire for a price tag of $32bn – closing an almost year-long deal discussion.
More from Business
More from Scrip
• By
The company plans a tiered sales approach as it targets endocrinologists for hypothalamic obesity, which is more widely diagnosed than its current indication for Bardet-Biedl syndrome.
• By
There were six biopharma initial public offerings on Western stock exchanges, including five in the US, during the first quarter, but plunging stock values could halt further IPOs.
• By
Sector-specific tariffs, including on pharmaceuticals, could be announced as early as this week.